154 related articles for article (PubMed ID: 24139214)
21. Immunophenotypic analysis of inflammatory breast cancers: identification of an 'inflammatory signature'.
Charafe-Jauffret E; Tarpin C; Bardou VJ; Bertucci F; Ginestier C; Braud AC; Puig B; Geneix J; Hassoun J; Birnbaum D; Jacquemier J; Viens P
J Pathol; 2004 Mar; 202(3):265-73. PubMed ID: 14991891
[TBL] [Abstract][Full Text] [Related]
22. Basal-like breast cancer: update on clinicopathologic, immunohistochemical, and molecular features.
Leidy J; Khan A; Kandil D
Arch Pathol Lab Med; 2014 Jan; 138(1):37-43. PubMed ID: 24377810
[TBL] [Abstract][Full Text] [Related]
23. Nerve growth factor receptor (NGFR): a potential marker for specific molecular subtypes of breast cancer.
Tsang JY; Wong KH; Lai MW; Lacambra MD; Ko CW; Chan SK; Lam CC; Yu AM; Tan PH; Tse GM
J Clin Pathol; 2013 Apr; 66(4):291-6. PubMed ID: 23268325
[TBL] [Abstract][Full Text] [Related]
24. The clinicopathological significance of CD44+/CD24-/low and CD24+ tumor cells in invasive micropapillary carcinoma of the breast.
Li W; Liu F; Lei T; Xu X; Liu B; Cui L; Wei J; Guo X; Lang R; Fan Y; Gu F; Tang P; Zhang X; Fu L
Pathol Res Pract; 2010 Dec; 206(12):828-34. PubMed ID: 20977976
[TBL] [Abstract][Full Text] [Related]
25. Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas.
Rodríguez-Pinilla SM; Sarrió D; Honrado E; Moreno-Bueno G; Hardisson D; Calero F; Benítez J; Palacios J
J Clin Pathol; 2007 Sep; 60(9):1006-12. PubMed ID: 17105822
[TBL] [Abstract][Full Text] [Related]
26. Retention of the expression of E-cadherin and catenins is associated with shorter survival in grade III ductal carcinoma of the breast.
Gillett CE; Miles DW; Ryder K; Skilton D; Liebman RD; Springall RJ; Barnes DM; Hanby AM
J Pathol; 2001 Apr; 193(4):433-41. PubMed ID: 11276001
[TBL] [Abstract][Full Text] [Related]
27. Correlation and expression of p53, HER-2, vascular endothelial growth factor (VEGF), and e-cadherin in a high-risk breast-cancer population.
Howard EM; Lau SK; Lyles RH; Birdsong GG; Tadros TS; Umbreit JN; Kochhar R
Int J Clin Oncol; 2004 Jun; 9(3):154-60. PubMed ID: 15221598
[TBL] [Abstract][Full Text] [Related]
28. A comprehensive morphological study for basal-like breast carcinomas with comparison to nonbasal-like carcinomas.
Cakir A; Gonul II; Uluoglu O
Diagn Pathol; 2012 Oct; 7():145. PubMed ID: 23082819
[TBL] [Abstract][Full Text] [Related]
29. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
[TBL] [Abstract][Full Text] [Related]
30. The hormone receptor, human epidermal growth factor receptor 2, and molecular subtype status of individual tumor foci in multifocal/multicentric invasive ductal carcinoma of breast.
Choi Y; Kim EJ; Seol H; Lee HE; Jang MJ; Kim SM; Kim JH; Kim SW; Choe G; Park SY
Hum Pathol; 2012 Jan; 43(1):48-55. PubMed ID: 21733550
[TBL] [Abstract][Full Text] [Related]
31. αB-crystallin is a useful marker for triple negative and basal breast cancers.
Tsang JY; Lai MW; Wong KH; Chan SK; Lam CC; Tsang AK; Yu AM; Tan PH; Tse GM
Histopathology; 2012 Sep; 61(3):378-86. PubMed ID: 22463677
[TBL] [Abstract][Full Text] [Related]
32. Clinical significance of basal-like subtype in triple-negative breast cancer.
Yamamoto Y; Ibusuki M; Nakano M; Kawasoe T; Hiki R; Iwase H
Breast Cancer; 2009; 16(4):260-7. PubMed ID: 19701681
[TBL] [Abstract][Full Text] [Related]
33. Triple-negative breast carcinoma: current and emerging concepts.
Schmadeka R; Harmon BE; Singh M
Am J Clin Pathol; 2014 Apr; 141(4):462-77. PubMed ID: 24619745
[TBL] [Abstract][Full Text] [Related]
34. Basal-HER2 phenotype shows poorer survival than basal-like phenotype in hormone receptor-negative invasive breast cancers.
Liu H; Fan Q; Zhang Z; Li X; Yu H; Meng F
Hum Pathol; 2008 Feb; 39(2):167-74. PubMed ID: 18045647
[TBL] [Abstract][Full Text] [Related]
35. Immunohistochemical identification of basal-type cytokeratins in invasive ductal breast carcinoma--relation with grade, stage, estrogen receptor and HER2.
Kusińska R; Potemski P; Jesionek-Kupnicka D; Kordek R
Pol J Pathol; 2005; 56(3):107-10. PubMed ID: 16334976
[TBL] [Abstract][Full Text] [Related]
36. Epithelial Paradox: Clinical Significance of Coexpression of E-cadherin and Vimentin With Regard to Invasion and Metastasis of Breast Cancer.
Yamashita N; Tokunaga E; Iimori M; Inoue Y; Tanaka K; Kitao H; Saeki H; Oki E; Maehara Y
Clin Breast Cancer; 2018 Oct; 18(5):e1003-e1009. PubMed ID: 29526677
[TBL] [Abstract][Full Text] [Related]
37. Molecular insights on basal-like breast cancer.
Valentin MD; da Silva SD; Privat M; Alaoui-Jamali M; Bignon YJ
Breast Cancer Res Treat; 2012 Jul; 134(1):21-30. PubMed ID: 22234518
[TBL] [Abstract][Full Text] [Related]
38. CD109 expression in basal-like breast carcinoma.
Hasegawa M; Moritani S; Murakumo Y; Sato T; Hagiwara S; Suzuki C; Mii S; Jijiwa M; Enomoto A; Asai N; Ichihara S; Takahashi M
Pathol Int; 2008 May; 58(5):288-94. PubMed ID: 18429827
[TBL] [Abstract][Full Text] [Related]
39. Frequent overexpression of epidermal growth factor receptor (EGFR) in mammary high grade ductal carcinomas with myoepithelial differentiation.
Shien T; Tashiro T; Omatsu M; Masuda T; Furuta K; Sato N; Akashi-Tanaka S; Uehara M; Iwamoto E; Kinoshita T; Fukutomi T; Tsuda H; Hasegawa T
J Clin Pathol; 2005 Dec; 58(12):1299-304. PubMed ID: 16311351
[TBL] [Abstract][Full Text] [Related]
40. Comparative study of primary mammary small cell carcinoma, carcinoma with endocrine features and invasive ductal carcinoma.
Yamamoto J; Ohshima K; Nabeshima K; Ikeda S; Iwasaki H; Kikuchi M
Oncol Rep; 2004 Apr; 11(4):825-31. PubMed ID: 15010880
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
